Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Key Points
Moderna's shares have been southbound for the past few years due to unimpressive financial results.
However, progress with the pipeline could significantly boost the stock over the next five years.
- 10 stocks we like better than Moderna ›
Long gone are the days when Moderna (NASDAQ: MRNA) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple of years, the company's revenue and earnings have plummeted along with its stock price.
Moderna is eager to prove its success wasn't just a one-off. And the company could achieve that goal in the next five years, leading to substantial stock-market returns over this period.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Clinical progress could jolt the stock
Moderna's impressive work in the coronavirus market wasn't a fluke. The company's mRNA platform allows it to develop vaccines faster than traditional, non-mRNA ones. And partly thanks to the windfall it experienced from its COVID vaccine, Moderna ramped up research and development (R&D) spending and expanded its pipeline.
These efforts have already started to pay off. The company has recorded important clinical and regulatory progress lately. That includes the approval of its vaccine for the respiratory syncytial virus (RSV), mResvia.
However, over the next five years, Moderna should see even more clinical wins for therapies that have far more commercial potential. One of the company's leading candidates is mRNA-4157, a personalized therapeutic cancer vaccine. In mid-stage studies, mRNA-4157 significantly reduced the risk of recurrence or death in melanoma patients when paired with Merck's Keytruda, compared to Keytruda alone.
mRNA-4157 is now undergoing a phase 3 study in this indication, but it's also being tested across many other types of cancer, including lung cancer, renal cell carcinoma, bladder cancer, and melanoma. This candidate's progress could power a strong streak of success for Moderna, leading to superior returns over the next five years.
Patience may pay off
Moderna has encountered some headwinds over the past couple of years. But the company's pipeline could get the stock out of trouble, as it allows the biotech to launch new candidates and generate significantly better financial results. The stock might not be performing well right now, patient shareholders could see significant gains down the road.
Should you invest $1,000 in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $669,449!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,110,486!*
Now, it’s worth noting Stock Advisor’s total average return is 1,076% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 20, 2025
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
Recommended Articles
